Syneos Health Stock Forecast, Price & News

Syneos Health's stock was trading at $57.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SYNH shares have decreased by 7.4% and is now trading at $53.08.
View which stocks have been most impacted by COVID-19.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Syneos Health.

Syneos Health is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for Syneos Health.

Syneos Health, Inc. (NASDAQ:SYNH) announced its quarterly earnings data on Thursday, October, 29th. The company reported $1.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.79 by $0.25. The company earned $1.10 billion during the quarter, compared to analysts' expectations of $1.12 billion. Syneos Health had a net margin of 4.10% and a return on equity of 9.63%. The company's revenue for the quarter was down 6.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.87 EPS.
View Syneos Health's earnings history.

Syneos Health updated its fourth quarter earnings guidance on Thursday, October, 29th. The company provided earnings per share guidance of $1.03-1.16 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.09. The company issued revenue guidance of $1.09-1.16 billion, compared to the consensus revenue estimate of $1.22 billion.

12 equities research analysts have issued 1-year target prices for Syneos Health's stock. Their forecasts range from $52.00 to $82.00. On average, they expect Syneos Health's share price to reach $68.00 in the next year. This suggests a possible upside of 28.1% from the stock's current price.
View analysts' price targets for Syneos Health.

Some companies that are related to Syneos Health include Incyte (INCY), Exact Sciences (EXAS), PPD (PPD), Charles River Laboratories International (CRL), ICON Public (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Medpace (MEDP), BTG (BTGGF), National Research (NRC), Precigen (PGEN), Starpharma (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA) and Pieris Pharmaceuticals (PIRS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA), Pfizer (PFE), Square (SQ), Advanced Micro Devices (AMD), The Boeing (BA), Alibaba Group (BABA), ICON Public (ICLR), Netflix (NFLX), AbbVie (ABBV) and Intel (INTC).

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

Syneos Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.50%), AMI Asset Management Corp (0.19%), Hennessy Advisors Inc. (0.17%), Kornitzer Capital Management Inc. KS (0.14%), Envestnet Asset Management Inc. (0.12%) and Retirement Systems of Alabama (0.09%). Company insiders that own Syneos Health stock include Alistair Macdonald, International Corp/Ma Advent, Jason M Meggs, John M Dineen, Jonathan Olefson, Michelle Keefe, Paul Colvin, Robert Parks and Thomas H Lee Advisors, Llc.
View institutional ownership trends for Syneos Health.

SYNH stock was sold by a variety of institutional investors in the last quarter, including Hennessy Advisors Inc., Dupont Capital Management Corp, New Mexico Educational Retirement Board, AMI Asset Management Corp, First Hawaiian Bank, State of New Jersey Common Pension Fund D, New Mexico Educational Retirement Board, and Buffington Mohr McNeal. Company insiders that have sold Syneos Health company stock in the last year include Alistair Macdonald, International Corp/Ma Advent, Michelle Keefe, Robert Parks, and Thomas H Lee Advisors, Llc.
View insider buying and selling activity for Syneos Health.

SYNH stock was bought by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, DekaBank Deutsche Girozentrale, Pacer Advisors Inc., Envestnet Asset Management Inc., Prudential PLC, Retirement Systems of Alabama, Campbell Newman Asset Management Inc., and Comerica Bank. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs, John M Dineen, Jonathan Olefson, and Paul Colvin.
View insider buying and selling activity for Syneos Health.

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SYNH stock can currently be purchased for approximately $53.08.

Syneos Health has a market capitalization of $5.55 billion and generates $4.68 billion in revenue each year. The company earns $131.26 million in net income (profit) each year or $2.83 on an earnings per share basis. Syneos Health employs 24,000 workers across the globe.

The official website for Syneos Health is www.syneoshealth.com.

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]